Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Status:
RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.